Given their robust oncogenic drive and pharmacologic targetability, kinase fusions have garnered substantial attention as therapeutic targets in cancer, including the noteworthy first fusion to be targeted, BCR-ABL, followed by ALK, ROS1, and NTRK fusions3–11. This evidence concerns the gene ALK and cancer.